



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

Is best transfusion practice alone best clinical practice?

Spahn, Donat R ; Vamvakas, Eleftherios C

Abstract: The review by Shander et al. in this issue of the journal highlights the progress made in transfusion medicine since the 1980s, including the tremendous decrease in the risk of transfusion-transmitted infections (TTIs) and the development of remarkably similar (and uniformly restrictive) transfusion guidelines by five major professional societies and the American Association of Blood Banks¹. These guidelines aim at reducing the number of a patient's allogeneic donor exposures as much as possible, by administering transfusion only when proven (rather than postulated) benefit can be expected from the transfusion. Proven benefit, exemplified by a red-blood-cell (RBC) transfusion to a stable and non-bleeding patient triggered by a haemoglobin of 7 g/dL, is based on findings from randomised controlled trials (RCTs) using clinical endpoints². (...)

DOI: <https://doi.org/10.2450/2012.0283-12>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-75211>

Journal Article

Published Version

Originally published at:

Spahn, Donat R; Vamvakas, Eleftherios C (2013). Is best transfusion practice alone best clinical practice? *Blood Transfusion*, 11(2):172-174.

DOI: <https://doi.org/10.2450/2012.0283-12>

Is best transfusion practice alone best clinical practice?

To cite this article:

DOI: 10.2450/2012.0283-12

Published online: 22/01/2013

Authors

Donat R. Spahn, Eleftherios C. Vamvakas

Abstract

The review by Shander *et al.* in this issue of the journal highlights the progress made in transfusion medicine since the 1980s, including the tremendous decrease in the risk of transfusion-transmitted infections (TTIs) and the development of remarkably similar (and uniformly restrictive) transfusion guidelines by five major professional societies and the American Association of Blood Banks¹. These guidelines aim at reducing the number of a patient's allogeneic donor exposures as much as possible, by administering transfusion only when proven (rather than postulated) benefit can be expected from the transfusion. Proven benefit, exemplified by a red-blood-cell (RBC) transfusion to a stable and non-bleeding patient triggered by a haemoglobin of 7 g/dL, is based on findings from randomised controlled trials (RCTs) using clinical endpoints². (...)

[Full Text](#)

[Home](#)

[Back](#)

Full Text

© SIMTI Servizi Srl

Is best transfusion practice alone best clinical practice?

Donat R. Spahn¹, Eleftherios C. Vamvakas²

¹Institute of Anaesthesiology and Head Medical, Section Anaesthesiology, Intensive Care Medicine and OR-Management, University and University Hospital Zurich, Zurich, Switzerland; ²Los Angeles, CA, United States of America

The review by Shander *et al.* in this issue of the journal highlights the progress made in transfusion medicine since the 1980s, including the tremendous decrease in the risk of transfusion-transmitted infections (TTIs) and the development of remarkably similar (and uniformly restrictive) transfusion guidelines by five major professional societies and the American Association of Blood Banks¹. These guidelines aim at reducing the number of a patient's allogeneic donor exposures as much as possible, by administering transfusion only when proven (rather than postulated) benefit can be expected from the transfusion. Proven benefit, exemplified by a red-blood-cell (RBC) transfusion to a stable and non-bleeding patient triggered by a haemoglobin of 7 g/dL, is based on findings from randomised controlled trials (RCTs) using clinical endpoints². In contrast, transfusing stable and non-bleeding patients at a haemoglobin of 8 g/dL and higher is largely based on postulated benefits based on what can be theoretically deduced from pathophysiology^{3,4}.

Adherence to these restrictive transfusion guidelines constitutes best transfusion practice, which may decrease mortality according to the findings of a recent meta-analysis of 19 RCTs enrolling over 6,000 subjects². The optimisation of transfusion practice that these restrictive transfusion triggers allow, however, does not remove the risks of RBC transfusion^{5,6}. The latter include the currently-leading causes of death from transfusion (transfusion-related acute lung injury, haemolytic transfusion reactions, and transfusion-associated circulatory overload), other

infectious and immunologic transfusion complications, as well as the cardinal threat to transfusion safety today, namely the next "HIV-like" pathogen to emerge in the future^{5,6}. For these reasons, best transfusion practice alone may not necessarily represent best clinical practice.

One reason why it is necessary to optimise clinical practice beyond the improvement afforded by the adoption of restrictive transfusion guidelines is that preoperative anaemia is a major risk factor for RBC transfusion⁷ and, in addition, even mild preoperative anaemia increases perioperative mortality and morbidity by at least 30%⁸. Detection and treatment of preoperative anaemia is thus a necessary component of best clinical practice. The success of this approach has been demonstrated by RCTs conducted in orthopaedic⁹ and cardiac surgery¹⁰. Preoperative treatment of anaemia reduced transfusion needs^{9,10}, decreased acute renal failure¹⁰ and correlated with reduced length of hospital stay¹⁰.

Another reason why best transfusion practice alone does not represent best clinical practice is that excessive blood loss and the need for early reoperation are independently associated with increased mortality, acute kidney injury¹¹, stroke and myocardial infarction¹². Blood loss can be reduced by blood-sparing surgical and anaesthetic blood-conservation techniques which minimise perioperative bleeding, while they optimise intraoperative cardiac output, ventilation and oxygenation. In addition, perioperative blood recovery reduces the need for RBC transfusion and the length of hospital stay¹³, making meticulous surgical and anaesthetic technique, as well as perioperative blood recovery where indicated, necessary components of best clinical practice. Indeed, the combination of preoperative treatment of anaemia, meticulous surgical and anaesthetic technique, perioperative blood recovery, and restrictive haemoglobin transfusion triggers has been shown to reduce RBC transfusion needs and the length of hospital stay, as well as to decrease mortality and costs¹³⁻¹⁶.

It is all these strategies together that represent best clinical practice, according to the concept of Patient Blood Management (PBM)¹⁷ adopted by the World Health Organization in 2010¹⁸. PBM identifies a patient at risk of transfusion and formulates a multidisciplinary and multimodal, yet individualised, plan for reducing or eliminating the need for allogeneic transfusion¹⁹. PBM encompasses the adoption of restrictive transfusion guidelines, but it includes a lot more than the mere adoption of restrictive transfusion guidelines¹³⁻²¹. In addition to transfusing only when proven benefit is expected, PBM encompasses treating anaemia and coagulopathy before admission to the hospital, minimising iatrogenic blood losses throughout the hospitalisation, using blood-sparing surgical and anaesthetic blood-conservation techniques, and employing perioperative blood recovery and acute normovolaemic haemodilution where indicated. In this way, PBM integrates many hospital departments and services in a common effort to reduce allogeneic-donor exposures as much as possible, and to thereby prevent the infectious and immunologic complications of transfusion.

When the standard for transfusion medicine is set as reducing the transfusion risk for each patient to the level of the "as-low-as-reasonably-achievable" (ALARA) risk²⁰⁻²², clinical practice has to be further improved by meeting a patient's allogeneic-transfusion needs through fewer donor exposures than the number mandated by the number of components that the patient receives. Hitherto, PBM has been mainly used to avoid RBC transfusion in surgical patients, but multicomponent apheresis can expand the domain of PBM to platelet and plasma transfusion and to medical patients^{20,21,23,24}. Multicomponent apheresis is now limited to collecting any combination of RBCs, platelets, and/or plasma from the same donor during the same donation (with at least 2 components collected from each donation: 2 RBC units, 2-3 plasma units, 2-3 platelet units or 1 RBC unit together with plasma and/or platelets)²⁴. In the future, all components collected from the same multicomponent apheresis donation should be reserved for transfusion to the same recipient^{20,21,23}. Because multitransfused patients –such as patients with acute blood loss– need multiple units of RBCs and plasma (and sometimes of platelets as well), multicomponent apheresis can reduce their number of donor exposures by at least 2-fold, thereby also reducing the risk of infectious and immunologic complications of transfusion by at least 2-fold^{20,21}.

Together, PBM and multicomponent apheresis represent a new paradigm –the patient-centric paradigm– of transfusion medicine that will hopefully replace the current (component-centric) paradigm in the 21st century^{20,21,25}. Whereas now each blood component is a drug to be dispensed, in the future we will hopefully be meeting each patient's transfusion needs through an individualised combination of (PBM and multicomponent-apheresis) approaches. Whereas our current focus is on the quality of the component, in the future we should concentrate on the quality of the medical service (or individualised combination of PBM and multicomponent-apheresis approaches) that we provide each patient. And whereas now our overriding concern is to avoid blood shortages, in the future should aim to reduce the transfusion risk for all patients to the level of the ALARA risk²⁰⁻²².

Conflict of interest statements

Donat R. Spahn's academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland (grant numbers: 33CM30_124117 and 406440-131268), the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland (no grant numbers are attributed), the Swiss Foundation for Anesthesia Research, Zurich, Switzerland (no grant numbers are attributed), Bundesprogramm Chancengleichheit, Berne, Switzerland (no grant numbers are attributed), CSL Behring, Berne, Switzerland (no grant numbers are attributed), Vifor SA, Villars-sur-Glâne, Switzerland (no grant numbers are attributed).

Dr. Spahn was the chairman of the ABC Faculty and is a member of the ABC Trauma Faculty which both are managed by Thomson Physicians World GmbH, Mannheim, Germany and sponsored by an unrestricted educational

grant from Novo Nordisk A/S, Bagsvård, Denmark and CSL Behring GmbH, Hattersheim am Main, Germany. In the past 5 years, Dr. Spahn has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland, AMGEN GmbH, Munich, Germany, AstraZeneca AG, Zug, Switzerland, Bayer (Schweiz) AG, Zürich, Switzerland, Baxter S.p.A., Roma, Italy, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Bern, Switzerland, Curacyte AG, Munich, Germany, Ethicon Biosurgery, Sommerville, New Jersey, USA, Fresenius SE, Bad Homburg v.d.H., Germany, Galenica AG, Berne, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland), GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany, Janssen-Cilag AG, Baar, Switzerland, Janssen-Cilag EMEA, Beerse, Belgium, Merck Sharp & Dohme-Chibret AG, Opfikon-Glattbrugg, Switzerland, Novo Nordisk A/S, Bagsvård, Denmark, Octapharma AG, Lachen, Switzerland, Organon AG, Pfäffikon/SZ, Switzerland, Oxygen Biotherapeutics, Costa Mesa, CA, Pentapharm GmbH (now tem Innovations GmbH), Munich, Germany, ratiopharm Arzneimittel Vertriebs-GmbH, Vienna, Austria, Roche Pharma (Schweiz) AG, Reinach, Switzerland, Schering-Plough International, Inc., Kenilworth, New Jersey, USA, Vifor Pharma Deutschland GmbH, Munich, Germany, Vifor Pharma Österreich GmbH, Vienna, Austria, Vifor (International) AG, St. Gallen, Switzerland.

E.C. Vamvakas has no conflict of interest of any kind.

References

- 1) Shander A, Gross I, Hill S et al. A New Perspective on Best Transfusion Practices. *Blood Transfus* DOI 12.2450/2012.0195-12.
- 2) Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev* 2012; **4**: CD002042.
- 3) Carson JL, Terrin ML, Noveck H et al. Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery. *N Engl J Med* 2011; **365**: 2453-62.
- 4) Shander A, Fink A, Javidroozi M et al. Appropriateness of Allogeneic Red Blood Cell Transfusion: The International Consensus Conference on Transfusion Outcomes. *Transfus Med Rev* 2011; **25**: 232.
- 5) Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. *Transfus Med Rev* 2010; **24**: 77-124.
- 6) Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. *Blood* 2009; **113**: 3406-17.
- 7) Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. *Transfusion* 2007; **47**: 1468-80.
- 8) Musallam KM, Tamim HM, Richards T et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet* 2011; **378**: 1396-407.
- 9) Na HS, Shin SY, Hwang JY et al. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. *Transfusion* 2011; **51**: 118-24.
- 10) Yoo YC, Shim JK, Kim JC et al. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. *Anesthesiology* 2011; **115**: 929-37.
- 11) Vivacqua A, Koch CG, Yousuf AM et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? *Ann Thorac Surg* 2011; **91**: 1780-90.
- 12) Kamel H, Johnston SC, Kirkham JC et al. Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction. *Circulation* 2012; **126**: 207-12.
- 13) Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. *Anesthesiology* 2010; **113**: 482-95.
- 14) Kotze A, Carter LA, Scally AJ. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. *Br J Anaesth* 2012; **108**: 943-52.
- 15) Moskowitz DM, McCullough JN, Shander A et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? *Ann Thorac Surg* 2010; **90**: 451-8.
- 16) Spahn DR, Theusinger OM, Hofmann A. Patient blood management is a win-win: a wake-up call. *Br J Anaesth* 2012; **108**: 889-92.
- 17) Gombotz H. Patient blood management is key before elective surgery. *Lancet* 2011; **378**: 1362-3.
- 18) World Health Assembly. Availability, safety and quality of blood products. 21 May 2010. Available at http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf. Accessed on 04/12/2012.
- 19) Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. *Oncologist* 2011; **16** (Suppl 3): 3-11.
- 20) Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. *Transfusion* 2012; DOI 10.1111/j.1537-2995.2012.03825.x.
- 21) Vamvakas EC. Paradigm shifts in transfusion medicine. In: Vamvakas EC. *Decision making in transfusion medicine*. Bethesda, MD: AABB Press; 2011. pp 265-305.
- 22) Leiss W, Tyshenko M, Krewski D. Men having sex with men donor deferral risk assessment: an analysis using risk management principles. *Transfus Med Rev*. 2008; **22**: 35-57.
- 23) Popovsky MA. Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention. *Transfus Med Hemother* 2008; **35**: 76-9.

- 24) Popovsky MA. Multicomponent apheresis blood collection in the United States: current status and future directions. *Transfus Apher Sci* 2005; **32**: 299-304.
- 25) Farrugia A. Falsification or paradigm shift? Toward a revision of the common sense of transfusion. *Transfusion* 2011; **51**: 216-24.